JHL Biotech, at December 15, 2017, has submitted a Phase I Clinical Trial Application (“CTA”) to European authorities for its proposed bevacizumab biosimilar, JHL1149.
This biologic can be used for treatment of many cancers, the most common of which are metastatic colorectal cancer, lung cancer, and ovarian cancer. In 2016, reference bevacizumab generated revenues of about US$7 billion.
JHL is planning to conduct a single-site three-arm pharmacokinetic study in healthy volunteers. The data from this trial will support the rapid development and commercialization of JHL1149.
“Bevacizumab is an important biologic that is, unfortunately, very expensive. JHL Biotech looks forward to making bevacizumab available to all who need it, and our JHL1149 European clinical trial is the first step in achieving this goal”, said Racho Jordanov, JHL Biotech’s CEO.
Media Contact:
Jill Liu, Amber Chen
jliu@jhlbiotech.com, achen@jhlbiotech.com
Phone: +886 3-658-3899
About JHL Biotech
JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech’s mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. For more information, please visit www.jhlbiotech.com.